MIRA (Mira Pharmaceuticals) Change In Receivables : $0.01 Mil (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mira Pharmaceuticals Change In Receivables?

Mira Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2024 was $0.00 Mil. It means Mira Pharmaceuticals's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Mira Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2024 was $0.01 Mil. It means Mira Pharmaceuticals's Accounts Receivable declined by $0.01 Mil from Dec. 2023 to Dec. 2024 .

Mira Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Mira Pharmaceuticals's liquidation value for the three months ended in Dec. 2024 was $2.11 Mil.

Mira Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Mira Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mira Pharmaceuticals Change In Receivables Chart

Mira Pharmaceuticals Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Change In Receivables

-0.01

0.01

Mira Pharmaceuticals Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial								-	0.01	-	-	-

Mira Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01 Mil.

Mira Pharmaceuticals (NAS:MIRA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Mira Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Mira Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Mira Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	2.833	-	0.723	+	0.75 * 0	+	0.5 * 0
=	2.11

Mira Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Mira Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Mira Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mira Pharmaceuticals Inc (NAS:MIRA) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

K6S:Germany

Address

1200 Brickell Avenue, Suite 1950 No. 1183, Miami, FL, USA, 33133

Website

https://www.mirapharmaceuticals.com

Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.

Executives

Erez Aminov	director, officer: Chief Executive Officer	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Brian Patrick Mcnulty	10 percent owner	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Brian Frederick Daly	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
George Cappy	10 percent owner	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
David C Vorhoff	director	C/O STAR SCIENTIFIC, INC., 801 LIBERTY WAY, CHESTER VA 23836
Chapman Christopher C Jr	director, officer: Executive Chairman	C/O STAR SCIENTIFIC, INC., 7475 WISCONSIN AVENUE, SUITE 850, BETHESDA MD 20814
Adam Kaplin	officer: Pres. & Chief Scientific Off.	C/O AKERS BIOSCIENCES, INC., 1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK NY 10036
Michelle Yanez	officer: CFO, Secretary & Treasurer	449 S. 12TH STREET UNIT 1705, TAMPA FL 33602
Hugh Iii Mccoll	director	100 RIVER BLUFF DRIVE, SUITE 210, LITTLE ROCK AR 72202
Christos Nicholoudis	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bradley Kroenig	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Talhia Tuck	director	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173
Bay Shore Trust	10 percent owner	C/O MIRA PHARMACEUTICALS, INC., 900 WEST PLATT STREET, SUITE 200, TAMPA FL 33606-2173